Literature DB >> 25284604

Hb Wilde and Hb Patagonia: two novel elongated beta-globin variants causing dominant beta-thalassemia.

Karen G Scheps1, Marcia A Hasenahuer2, Gustavo Parisi2, María S Fornasari2, Sandra P Pennesi3, Beatriz Erramouspe4, Felisa N Basack3, Ernesto S Veber5, Luis Aversa3, Graciela Elena5, Viviana Varela1.   

Abstract

We describe here the molecular and hematological characteristics of novel frameshift mutations in exon 2 of the HBB gene (in heterozygous state) found in two Argentinean pediatric patients with dominant β-thalassemia-like features. In Hb Wilde, HBB:c.270_273delTGAG(p.Glu90Cysfs*67), we detected the deletion of the third base of the codon 89 (T) and the codon 90 (GAG), whereas in Hb Patagonia, HBB:c.296_297dupGT(p.Asp99Trpfs*59), the frameshift mutation was due to a duplication of a 'GT' dinucleotide after the second base of codon 98 (GTG). The Hb Patagonia and Hb Wilde mutations would result in elongated β-globin chains with modified C-terminal sequences and a total of 155 and 157 amino acids residues, respectively. Based on bioinformatics and structural analysis, as well as protein modeling, we predict that the elongated β-globins would affect the formation of the αβ dimers and their stability, which would further support the mechanism for the observed clinical features in both patients.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  HBB gene; dominant beta-thalassemia; elongated beta-globin variant; hemolytic anemia

Mesh:

Substances:

Year:  2014        PMID: 25284604     DOI: 10.1111/ejh.12456

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  1 in total

1.  Molecular epidemiology, pathogenicity, and structural analysis of haemoglobin variants in the Yunnan province population of Southwestern China.

Authors:  Jie Zhang; Peng Li; Yang Yang; Yuanlong Yan; Xiaohong Zeng; Dongmei Li; Hong Chen; Jie Su; Baosheng Zhu
Journal:  Sci Rep       Date:  2019-06-04       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.